<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Thorac Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">Thorac Cancer</journal-id>
      <journal-id journal-id-type="doi">10.1111/(ISSN)1759-7714</journal-id>
      <journal-id journal-id-type="publisher-id">TCA</journal-id>
      <journal-title-group>
        <journal-title>Thoracic Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1759-7706</issn>
      <issn pub-type="epub">1759-7714</issn>
      <publisher>
        <publisher-name>John Wiley &amp; Sons Australia, Ltd</publisher-name>
        <publisher-loc>Melbourne</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27807951</article-id>
      <article-id pub-id-type="pmc">5093177</article-id>
      <article-id pub-id-type="doi">10.1111/1759-7714.12380</article-id>
      <article-id pub-id-type="publisher-id">TCA12380</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Case Report</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Case Reports</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Complete remission of liver metastasis in a lung cancer patient with epidermal growth factor mutation achieved with <styled-content style="fixed-case">I</styled-content>cotinib</article-title>
        <alt-title alt-title-type="right-running-head">Liver metastasis in lung cancer</alt-title>
        <alt-title alt-title-type="left-running-head">Z. Zhu &amp; Y. Chai</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="tca12380-cr-0001" contrib-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>Zhouyu</given-names>
          </name>
          <xref ref-type="aff" rid="tca12380-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="tca12380-cr-0002" contrib-type="author" corresp="yes">
          <name>
            <surname>Chai</surname>
            <given-names>Ying</given-names>
          </name>
          <address>
            <email>chai_y@126.com</email>
          </address>
          <xref ref-type="aff" rid="tca12380-aff-0001">
<sup>1</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="tca12380-aff-0001">
        <label>
          <sup>1</sup>
        </label>
        <named-content content-type="organisation-division">Department of Thoracic Surgery, The Second Affiliated Hospital, College of Medicine</named-content>
        <institution>Zhejiang University</institution>
        <named-content content-type="city">Hangzhou</named-content>
        <country country="CN">China</country>
      </aff>
      <author-notes>
        <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Ying Chai, Department of Thoracic Surgery, The Second Affiliated Hospital, College of Medicine, Zhejiang University, # 88 Jiefang Road, Hangzhou 310009, China.<break/>
Tel: +86 571 8778 3642<break/>
Fax: +86 571 8778 3318<break/>
Email: <email>chai_y@126.com</email><break/></corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>04</day>
        <month>8</month>
        <year>2016</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2016</year>
      </pub-date>
      <volume>7</volume>
      <issue>6</issue>
      <issue-id pub-id-type="doi">10.1111/tca.2016.7.issue-6</issue-id>
      <fpage>681</fpage>
      <lpage>683</lpage>
      <history>
        <date date-type="received">
          <day>07</day>
          <month>5</month>
          <year>2016</year>
        </date>
        <date date-type="accepted">
          <day>23</day>
          <month>6</month>
          <year>2016</year>
        </date>
      </history>
      <permissions>
        <!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2016 China Lung Oncology Group and Wiley Publishing Asia Pty Ltd <copyright-statement>-->
        <copyright-statement content-type="article-copyright">&#xA9; 2016 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley &amp; Sons Australia, Ltd</copyright-statement>
        <license license-type="creativeCommonsBy-nc">
          <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">Creative Commons Attribution&#x2010;NonCommercial</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:type="simple" xlink:href="file:TCA-7-681.pdf"/>
      <abstract>
        <p>A 65&#x2010;year&#x2010;old <styled-content style="fixed-case">C</styled-content>hinese male was referred to our hospital for epidermal growth factor receptor (<styled-content style="fixed-case">EGFR)</styled-content>&#x2010;mutated advanced non&#x2010;small cell lung cancer (<styled-content style="fixed-case">NSCLC</styled-content>). Aggressive combined therapy with surgical resection of the right upper lung lesion and chemotherapy was performed. One&#x2009;month later, continued <styled-content style="fixed-case">I</styled-content>cotinib treatment was used as magnetic resonance imaging revealed liver metastasis (<styled-content style="fixed-case">LM</styled-content>). Interestingly, complete remission of the patient's <styled-content style="fixed-case">LM</styled-content> lesions was achieved in six&#x2009;months. To our knowledge, this is the first report documenting a successful case of an <styled-content style="fixed-case">NSCLC</styled-content> patient with <styled-content style="fixed-case">LM</styled-content> treated with <styled-content style="fixed-case">I</styled-content>cotinib after receiving a radical resection for pulmonary carcinoma. Our experience could provide a treatment strategy for patients with similar disease.</p>
      </abstract>
      <kwd-group kwd-group-type="author-generated">
        <kwd id="tca12380-kwd-0001"><styled-content style="fixed-case">A</styled-content>denocarcinoma</kwd>
        <kwd id="tca12380-kwd-0002">
          <styled-content style="fixed-case">EGFR</styled-content>
        </kwd>
        <kwd id="tca12380-kwd-0003"><styled-content style="fixed-case">I</styled-content>cotinib</kwd>
        <kwd id="tca12380-kwd-0004">liver metastasis</kwd>
        <kwd id="tca12380-kwd-0005">
          <styled-content style="fixed-case">TKI</styled-content>
        </kwd>
      </kwd-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="0"/>
        <page-count count="3"/>
        <word-count count="3000"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>component-id</meta-name>
          <meta-value>tca12380</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>November 2016</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.6 mode:remove_FC converted:03.11.2016</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="tca12380-sec-0001">
      <title>Introduction</title>
      <p>Cancer is the leading cause of death worldwide, with about 20% related to lung cancer. The most common extra&#x2010;pulmonary sites of distant metastasis in non&#x2010;small cell lung cancer (NSCLC) patients are the brain, bone, adrenal gland, and liver. In the past decade, epidermal growth factor receptor&#x2010;tyrosine kinase inhibitors (EGFR&#x2010;TKIs) have become widely used for the treatment of advanced NSCLC. However, the effect of EGFR&#x2010;TKI treatment in patients with EGFR&#x2010;mutated lung adenocarcinoma with liver metastasis (LM) after surgical resection of the lung cancer lesions is unclear.</p>
    </sec>
    <sec id="tca12380-sec-0002">
      <title>Case report</title>
      <p>In February 2015, a 65&#x2010;year&#x2010;old asymptomatic male smoker was admitted to our hospital, after being diagnosed with lung cancer at Sir Run Run Shaw Hospital. The patient denied any other medical history. On hospital admission, physical examination and laboratory test results were normal. A chest computed tomographic scan revealed an oblong lesion in the right upper lobe of the lung measuring 3.4&#x2009;cm&#x2009;&#xD7;&#x2009;1.6&#x2009;cm&#x2009;&#xD7;&#x2009;2.1&#x2009;cm and the right hilar lymph nodes were enlarged (Fig<xref rid="tca12380-fig-0001" ref-type="fig">1</xref>a,b). Bronchoalveolar lavage was performed and histopathologic examination indicated NSCLC. No distant metastases were found outside the lung during examination. After obtaining the patient's informed consent, a radical resection of the right upper pulmonary carcinoma and mediastinal lymph node dissection by video&#x2010;assisted thoracic surgery was performed. Histopathologic examination showed a 3.0&#x2009;cm&#x2009;&#xD7;&#x2009;2.0&#x2009;cm middle to well&#x2010;differentiated adenocarcinoma of the right upper lobe (Fig <xref rid="tca12380-fig-0001" ref-type="fig">1</xref>g). Thirty&#x2010;eight resected lymph nodes were detected and 10 were positive. The right upper lobe lesion carried an EGFR exon 19 deletion (Fig <xref rid="tca12380-fig-0001" ref-type="fig">1</xref>h). According to the 2015 National Comprehensive Cancer Network guidelines for NSCLC, chemotherapy was intravenously administered (pemetrexed 800&#x2009;mg day 1&#x2009;+&#x2009;cisplatinum 40&#x2009;mg days 2&#x2013;3) after the surgery. However, in March 2015, magnetic resonance imaging (MRI) revealed multiple lesions detected in the liver, which were considered to be metastases (Fig <xref rid="tca12380-fig-0001" ref-type="fig">1</xref>c,e). Considering that the right upper lung cancer was positive for EGFR mutations, the patient began treatment of 375&#x2009;mg Icotinib daily, from March 2015. Interestingly, after six&#x2009;months of therapy, liver MRI showed that the multiple lesions had vanished (Fig <xref rid="tca12380-fig-0001" ref-type="fig">1</xref>d,f). The patient is currently receiving maintenance Icotinib treatment and no new metastases have been found in 16&#x2009;months.</p>
      <fig fig-type="Figure" xml:lang="en" id="tca12380-fig-0001" orientation="portrait" position="float">
        <label>Figure 1</label>
        <caption>
          <p>. (<bold>a</bold>
<bold>,</bold>
<bold>b</bold>) Computed tomographic scan obtained February 2015, showing an oblong lesion in the right upper lobe measuring 3.4&#x2009;cm&#x2009;&#xD7;&#x2009;1.6 cm&#x2009;&#xD7;&#x2009;2.1&#x2009;cm. (<bold>c</bold>
<bold>,</bold>
<bold>e</bold>) Liver magnetic resonance imaging (MRI) obtained March 2015, showing multiple lesions in the liver. (<bold>d</bold>
<bold>,</bold>
<bold>f</bold>) Liver MRI after six&#x2009;months of Icotinib treatment; the multiple lesions in the liver have vanished. (<bold>g</bold>) Histopathologic examination of the oblong lesion in the right upper lobe showed middle to well&#x2010;differentiated adenocarcinoma (hematoxylin and eosin; &#xD7;100). (<bold>h</bold>) Epidermal growth factor receptor <bold>(</bold>EGFR) exon 19 microdeletion (delE746&#x2010;A750) detected by direct Sanger sequencing of biopsied samples from the right upper lobe lesion.</p>
        </caption>
        <graphic id="nlm-graphic-1" xlink:href="TCA-7-681-g001"/>
      </fig>
    </sec>
    <sec id="tca12380-sec-0003">
      <title>Discussion</title>
      <p>The incidence of LM in NSCLC patients is 20&#x2013;40%.<xref rid="tca12380-bib-0001" ref-type="ref">1</xref>, <xref rid="tca12380-bib-0002" ref-type="ref">2</xref> Patients with an EGFR mutation tend to have synchronous LM.<xref rid="tca12380-bib-0003" ref-type="ref">3</xref> For the past few years, many trials have demonstrated that advanced NSCLC patients with EGFR mutations could clinically benefit from receiving first&#x2010;line treatment with EGFR&#x2010;TKIs, such as afatinib, gefitinib, or erlotinib.<xref rid="tca12380-bib-0004" ref-type="ref">4</xref>, <xref rid="tca12380-bib-0005" ref-type="ref">5</xref>, <xref rid="tca12380-bib-0006" ref-type="ref">6</xref> Nevertheless, in stage IV lung adenocarcinoma patients, LM predicts poorer PFS and OS, despite treatment of susceptible gene mutations with first&#x2010;line EGFR&#x2010;TKIs.<xref rid="tca12380-bib-0007" ref-type="ref">7</xref> Although patients with liver metastasis on initial diagnosis have shorter PFS and OS than patients without liver metastasis, they could also benefit from first&#x2010;line treatment with EGFR&#x2010;TKIs. To our knowledge, no case of LM lesions in an NSCLC patient achieving complete remission by Icotinib treatment after radical resection of pulmonary carcinoma has previously been reported.</p>
      <p>Following a traditional therapeutic method, the patient may receive chemotherapy, radiofrequency ablation, or transcatheter arterial chemoembolization after undergoing radical resection of pulmonary carcinoma. However, because the tumor was positive for an EGFR mutation of exon 19 deletion in our case, we developed a strategy that involved continued Icotinib treatment for the liver lesions after radical resection of the pulmonary carcinoma.</p>
      <p>Early clinical data has shown that EFGR&#x2010;TKIs, including icotinib, gefitinib, and erlotinib, are mainly metabolized in the liver. Liver dysfunction may contribute to drug overexposure.<xref rid="tca12380-bib-0008" ref-type="ref">8</xref>, <xref rid="tca12380-bib-0009" ref-type="ref">9</xref>, <xref rid="tca12380-bib-0010" ref-type="ref">10</xref> Thus, it could be hypothesized that drug overexposure may lead to the higher curative effect of EGFR&#x2010;TKIs in patients with liver dysfunction caused by LM.</p>
      <p>In our case, the patient underwent radical resection of the pulmonary carcinoma before receiving EGFR&#x2010;TKI treatment. It could be hypothesized that resection of the pulmonary carcinoma leads to a higher curative effect of EGFR&#x2010;TKIs, as it lightens the tumor load on the patient; however, further study needs to be conducted to confirm this hypothesis.</p>
      <p>This case demonstrated the curative effect of EGFR&#x2010;TKIs for NSCLC patients with LM, after radical resection for pulmonary carcinoma. Doctors could consider this treatment strategy for patients with similar disease. To date, the patient is still alive, receiving Icotinib treatment, with no further metastasis. Further study is warranted.</p>
    </sec>
    <sec id="tca12380-sec-0004">
      <title>Disclosure</title>
      <p>No authors report any conflict of interest.</p>
    </sec>
  </body>
  <back>
    <ref-list id="tca12380-bibl-0001" content-type="cited-references">
      <title>References</title>
      <ref id="tca12380-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0001">
<string-name>
<surname>Quint</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Tummala</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Brisson</surname>
<given-names>LJ</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Distribution of distant metastases from newly diagnosed non&#x2010;small cell lung cancer</article-title>. <source>Ann Thorac Surg</source>
<year>1996</year>; <volume>62</volume>: <fpage>246</fpage>&#x2013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">8678651</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0002">
<string-name>
<surname>Hoang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Schiller</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Bonomi</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Johnson</surname>
<given-names>DH</given-names>
</string-name>. <article-title>Clinical model to predict survival in chemonaive patients with advanced non&#x2010;small cell lung cancer treated with third&#x2010;generation chemotherapy regimens based on Eastern Cooperative Oncology Group data</article-title>. <source>J Clin Oncol</source>
<year>2005</year>; <volume>23</volume>: <fpage>175</fpage>&#x2013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">15625371</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0003">
<string-name>
<surname>Tseng</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Chiou</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>YC</given-names>
</string-name>, <string-name>
<surname>Perng</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Jacqueline</surname>
<given-names>WP</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>YM</given-names>
</string-name>. <article-title>Number of liver metastatic nodules affects treatment options for pulmonary adenocarcinoma patients with liver metastases</article-title>. <source>Lung Cancer</source>
<year>2014</year>; <volume>86</volume>: <fpage>225</fpage>&#x2013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">25240517</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0004">
<string-name>
<surname>Rosell</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Carcereny</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Gervais</surname>
<given-names>R</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Erlotinib versus standard chemotherapy as first&#x2010;line treatment for European patients with advanced EGFR mutation&#x2010;positive non&#x2010;small&#x2010;cell lung cancer (EURTAC): A multicentre, open&#x2010;label, randomised phase 3 trial</article-title>. <source>Lancet Oncol</source>
<year>2012</year>; <volume>13</volume>: <fpage>239</fpage>&#x2013;<lpage>46</lpage>.<pub-id pub-id-type="pmid">22285168</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0005">
<string-name>
<surname>Maemondo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Inoue</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kobayashi</surname>
<given-names>K</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Gefitinib or chemotherapy for non&#x2010;small&#x2010;cell lung cancer with mutated EGFR</article-title>. <source>N Engl J Med</source>
<year>2010</year>; <volume>362</volume>: <fpage>2380</fpage>&#x2013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">20573926</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0006">
<string-name>
<surname>Sequist</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Yamamoto</surname>
<given-names>N</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations</article-title>. <source>J Clin Oncol</source>
<year>2013</year>; <volume>31</volume>: <fpage>3327</fpage>&#x2013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">23816960</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0007">
<string-name>
<surname>Wua</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Tsai</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>CJ</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first&#x2010;line gefitinib</article-title>. <source>Lung Cancer</source>
<year>2015</year>; <volume>88</volume>: <fpage>187</fpage>&#x2013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">25747806</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0008">
<string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Hidalgo</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Baker</surname>
<given-names>SD</given-names>
</string-name>. <article-title>Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes</article-title>. <source>Clin Cancer Res</source>
<year>2007</year>; <volume>13</volume>: <fpage>3731</fpage>&#x2013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">17575239</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0009">
<string-name>
<surname>Miller</surname>
<given-names>AA</given-names>
</string-name>, <string-name>
<surname>Murry</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Owzar</surname>
<given-names>K</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101</article-title>. <source>J Clin Oncol</source>
<year>2007</year>; <volume>25</volume>: <fpage>3055</fpage>&#x2013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">17634483</pub-id></mixed-citation>
      </ref>
      <ref id="tca12380-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="tca12380-cit-0010">
<string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>DY</given-names>
</string-name>
<italic>et al.</italic>
<article-title>Therapeutic effects and adverse drug reactions are affected by icotinib exposure and CYP2C19 and EGFR genotypes in Chinese non&#x2010;small cell lung cancer patients</article-title>. <source>Asian Pac J Cancer Prev</source>
<year>2014</year>; <volume>15</volume>: <fpage>7195</fpage>&#x2013;<lpage>200</lpage>.<pub-id pub-id-type="pmid">25227813</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
